PG
PTLA

PEAK6 Group’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

PEAK6 Group’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-70,200
Closed -$1.43M – 4993
2016
Q1 		$1.43M Buy
+70,200
New +$2.23M 0.01% 1395
2015
Q4 		– Sell
-6,100
Closed -$260K – 5547
2015
Q3 		$260K Buy
+6,100
New +$294K ﹤0.01% 3507

Other funds holding PTLA

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PEAK6 Group's PTLA Position: Q2 2016 in Review

PEAK6 Group sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2016, closing a stake of 14,858 shares — an estimated $303K sold.

PEAK6 Group first reported a position in PTLA in Q2 2013 and held it in 3 quarters. The position peaked at $303K in Q1 2016. 159 funds tracked by Wall St. Rank hold PTLA as of Q2 2016.

  • PEAK6 Group reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
  • PEAK6 Group sold 14,858 Portola Pharmaceuticals, Inc. shares in Q2 2016, an estimated $303K.
  • PEAK6 Group first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 3 quarters.
  • PEAK6 Group's Portola Pharmaceuticals, Inc. position peaked at $303K in Q1 2016.
  • 159 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2016.

Based on PEAK6 Group's 13F filing for Q2 2016, filed 10 Aug 2016.